Effectiveness of Mindfulness-Based Relapse Prevention Program as an Adjunct to the Standard Treatment for Smoking: A Pragmatic Design Pilot Study
| Autor: | Laisa Marcorela Andreoli Sartes, Elisa Harumi Kozasa, Ana Regina Noto, Isabel Cristina Weiss de Souza, Fernando Antonio Basile Colugnati, Sarah Bowen, Kimber P. Richter |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Mindfulness media_common.quotation_subject medicine.medical_treatment 030508 substance abuse Craving Pilot Projects Relapse prevention law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Recurrence Internal medicine Secondary Prevention Tobacco Smoking Medicine Humans 030212 general & internal medicine media_common Intention-to-treat analysis Cognitive Behavioral Therapy business.industry Standard treatment Public Health Environmental and Occupational Health Abstinence Middle Aged Smoking cessation Female medicine.symptom 0305 other medical science business Brazil |
| Zdroj: | Nicotinetobacco research : official journal of the Society for Research on Nicotine and Tobacco. 22(9) |
| ISSN: | 1469-994X 0232-7104 |
| Popis: | Introduction Posttreatment relapse is a major roadblock to stemming the global epidemic of tobacco-related illness. This article presents results from a pilot trial evaluating the feasibility and initial efficacy of Mindfulness-Based Relapse Prevention (MBRP) as an adjunct to standard relapse prevention treatment (ST) for smoking cessation. Aims and Methods Smokers (n = 86) in the maintenance phase of treatment were randomized to receive either ST plus MBRP (MBRP) (n = 44) or ST alone (ST) (n = 42). Data were collected at baseline and at 4-, 12-, and 24-week follow-up points. We evaluated the feasibility of the protocol with frequency analysis, and the efficacy with both intention to treat and complete case analyses of the effects of MBRP on abstinence. Secondary outcomes included mindfulness, craving, depression, anxiety, and positive/negative affect. Results High adherence suggested MBRP is acceptable and feasible. Participants in the MBRP group reported increases in mindfulness (M = −7.833, p = .016), and reductions in craving (M = 17.583, p = .01) compared with the ST group. Intention to treat analysis found that, compared with MBRP (36.4%), ST (57.1%) showed trend-level superiority in abstinence at Week 4 (Prevalence Ratio = 0.63, p = .06); however at Week 24, the ST group (14.3%) demonstrated a twofold greater decrease in abstinence, compared with the MBRP group (20.1%) (Prevalence Ratio = 2.25, p = .08). Therefore, the MBRP group maintained a higher abstinence rate for longer. Reported effects were greater in the complete case analysis. Conclusions MBRP holds promise for preventing relapse after aided tobacco quit attempts. Implications Findings suggest that MBRP is acceptable, feasible, and valued by participants. At 24-week follow-up, there was a large effect size and a statistical trend toward fewer MBRP patients relapsing compared with ST patients. MBRP conferred ancillary benefits including reductions in craving and increases in levels of mindfulness. MBRP for tobacco cessation is highly promising and merits further research. Trial Registration clinicaltrials.gov. Identifier NCT02327104. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|